Phase I/II randomized controlled trial of autologous bone marrow-derived mesenchymal stem cell therapy for chronic stroke

Table 2 Modified Barthel indices of the treatment group (n = 5) having mesenchymal stem cell therapy at the 1^st, 12^th, 16^th, 24^th, 36^th and 60^th week upon completion of the study

Study duration (wk)	Modified barthel indices					P value
	UPN02	UPN08	UPN09	UPN10	UPN11
1st	19	66	0	4	69
12th	19	73	0	5	70	0.12
16th	30	76	0	5	77	0.03
24th	32	76	0	5	77	0.03
36th	32	78	1	6	77	0.02
60th	32	78	1	-	77	0.03

Data derived from different time points were compared to the baseline values established at the first week of the study.